Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial Novadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million Phase Four unveils game changing engine for LEO Constellations Ventyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958
Back To News
BrightVolt expands R&D capabilities with new equipment
April 5, 2018

BrightVolt expands R&D capabilities with new equipment

arbin-logo

In Q1 of 2018 BrightVolt added technical personnel and made a substantial investment in new equipment to enhance our solid state battery development. This will help us improve the energy density and performance of our new solid state rechargeable batteries. BrightVolt’s first rechargeable batteries are expected to debut in Q3 of this year.

Our new solid state rechargeable battery product line will benefit from a new Keyence Digital Microscope, a new Metrohm Microcell HD, an additional Arbin 128 channel battery test system, and a new Branson ultrasonic welder. 

Cookie Policy Privacy Policy